Logo image of CHRO

CHANNEL THERAPEUTICS CORP (CHRO) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:CHRO - US1711261057 - Common Stock

1.35 USD
+0.09 (+7.14%)
Last: 7/1/2025, 9:36:41 PM
1.3699 USD
+0.02 (+1.47%)
After Hours: 7/1/2025, 9:36:41 PM
Fundamental Rating

0

Overall CHRO gets a fundamental rating of 0 out of 10. We evaluated CHRO against 533 industry peers in the Biotechnology industry. CHRO may be in some trouble as it scores bad on both profitability and health. CHRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CHRO had negative earnings in the past year.
CHRO had a negative operating cash flow in the past year.
In the past 5 years CHRO always reported negative net income.
CHRO had a negative operating cash flow in each of the past 5 years.
CHRO Yearly Net Income VS EBIT VS OCF VS FCFCHRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

With a Return On Assets value of -810.01%, CHRO is not doing good in the industry: 97.33% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -810.01%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHRO Yearly ROA, ROE, ROICCHRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

CHRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CHRO Yearly Profit, Operating, Gross MarginsCHRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

CHRO has more shares outstanding than it did 1 year ago.
CHRO has a better debt/assets ratio than last year.
CHRO Yearly Shares OutstandingCHRO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M
CHRO Yearly Total Debt VS Total AssetsCHRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 500K 1M 1.5M 2M

2.2 Solvency

CHRO has an Altman-Z score of -65.44. This is a bad value and indicates that CHRO is not financially healthy and even has some risk of bankruptcy.
CHRO's Altman-Z score of -65.44 is on the low side compared to the rest of the industry. CHRO is outperformed by 94.48% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -65.44
ROIC/WACCN/A
WACCN/A
CHRO Yearly LT Debt VS Equity VS FCFCHRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

2.3 Liquidity

A Current Ratio of 0.18 indicates that CHRO may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.18, CHRO is doing worse than 95.73% of the companies in the same industry.
CHRO has a Quick Ratio of 0.18. This is a bad value and indicates that CHRO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CHRO (0.18) is worse than 95.55% of its industry peers.
Industry RankSector Rank
Current Ratio 0.18
Quick Ratio 0.18
CHRO Yearly Current Assets VS Current LiabilitesCHRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

CHRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -197.60%.
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CHRO will show a small growth in Earnings Per Share. The EPS will grow by 5.16% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.62%
EPS Next 2Y5.98%
EPS Next 3Y5.16%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CHRO Yearly Revenue VS EstimatesCHRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 50K 100K 150K
CHRO Yearly EPS VS EstimatesCHRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CHRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CHRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHRO Price Earnings VS Forward Price EarningsCHRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CHRO Per share dataCHRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.98%
EPS Next 3Y5.16%

More info and screens

0

5. Dividend

5.1 Amount

CHRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHANNEL THERAPEUTICS CORP

NYSEARCA:CHRO (7/1/2025, 9:36:41 PM)

After market: 1.3699 +0.02 (+1.47%)

1.35

+0.09 (+7.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)N/A N/A
Inst Owners9.43%
Inst Owner Change-100%
Ins Owners14.91%
Ins Owner Change0%
Market Cap8.14M
Revenue(TTM)N/A
Net Income(TTM)-7.38M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0
BVpS-0.7
TBVpS-0.7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -810.01%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.18
Quick Ratio 0.18
Altman-Z -65.44
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.21%
EPS Next Y-3.62%
EPS Next 2Y5.98%
EPS Next 3Y5.16%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-196.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.4%
OCF growth 3YN/A
OCF growth 5YN/A

CHANNEL THERAPEUTICS CORP / CHRO FAQ

Can you provide the ChartMill fundamental rating for CHANNEL THERAPEUTICS CORP?

ChartMill assigns a fundamental rating of 0 / 10 to CHRO.


Can you provide the valuation status for CHANNEL THERAPEUTICS CORP?

ChartMill assigns a valuation rating of 0 / 10 to CHANNEL THERAPEUTICS CORP (CHRO). This can be considered as Overvalued.


What is the profitability of CHRO stock?

CHANNEL THERAPEUTICS CORP (CHRO) has a profitability rating of 0 / 10.


Can you provide the financial health for CHRO stock?

The financial health rating of CHANNEL THERAPEUTICS CORP (CHRO) is 0 / 10.


What is the earnings growth outlook for CHANNEL THERAPEUTICS CORP?

The Earnings per Share (EPS) of CHANNEL THERAPEUTICS CORP (CHRO) is expected to decline by -3.62% in the next year.